Table 2 Effect of apoE isoform on soluble exogenous apoE/Aβ complex levels

Naslund et al, 1995 [36]

Human brain (AD & NAD)

SDS-PAGE (Non-reducing), WB

AD > NAD, No apoE isoform differences measured

Russo et al, 1998 [46]

Human brain (AD & NAD)

IP, SDS-PAGE ^{(Non-reducing?),} WB

NAD apoE23/Aβ = NAD apoE33/Aβ = NAD apoE34/Aβ >>

AD apoE33/Aβ > AD apoE44/Aβ

SDS & protease digestion stability: NAD > AD

Yamauchi et al, 1999 [48]

Human CSF & serum (NAD)

SDS-PAGE (Non-reducing), WB

apoE33/Aβ > apoE44/Aβ (ND)

Hashimoto et al, 2012 [27]

Human brain (NAD)

SEC, SDS-PAGE (Reducing), WB

No complex measured, HMW Aβ interacts with apoE on HDL particles

LaDu et al, 2012 [63]

Human plasma (NAD)

SEC, SDS-PAGE (Non-reducing), WB

95% Aβ elutes with lipoproteins

Human CSF (NAD)

100% Aβ associated with apoE containing lipoproteins, apoE monomer/Aβ (45 kDa) & apoE dimer/Aβ (97 kDa) detected

Tai et al, 2013 [4]

Hippocampal homogenates (EFAD mice)

ELISA

SDS stable: E2FAD > E3FAD > E4FAD Total complex: E2FAD = E3FAD > E4FAD

Human cortical synaptosomes (AD & NAD)

Total complex:

• NAD > AD

• NAD apoE33/Aβ = NAD apoE4X/Aβ > > AD apoE33/Aβ > AD apoE4X/Aβ

SDS stable:

• NAD apoE33/Aβ > > NAD apoE4X/Aβ & AD apoE33/Aβ > AD apoE4X/Aβ

Human CSF (AD & NAD)

• NAD apoE33/Aβ > > NAD apoE4X/Aβ

Verghese, et al, 2013 [65]

Human CSF (NAD)

SEC, ELISA

95% Aβ (free) > > apoE33/Aβ = apoE44/Aβ

No apoE isoform differences

^{(In co-elution peak stoichiometric ratio of apoE:Aβ = 1:0.0002-0.0003)}